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Background: Lifestyle factors, including food and nutrition, physical activity, body composition and reproductive
factors, and single nucleotide polymorphisms (SNPs) are associated with breast cancer risk, but few studies of these
factors have been performed in the Japanese population. Thus, the goals of this study were to validate the
association between reported SNPs and breast cancer risk in the Japanese population and to evaluate the effects of
SNP genotypes and lifestyle factors on breast cancer risk.
Methods: A case–control study in 472 patients and 464 controls was conducted from December 2010 to
November 2011. Lifestyle was examined using a self-administered questionnaire. We analyzed 16 breast cancer-associated
SNPs based on previous GWAS or candidate-gene association studies. Age or multivariate-adjusted odds ratios
(OR) and 95% confidence intervals (95% CI) were estimated from logistic regression analyses.
Results: High BMI and current or former smoking were significantly associated with an increased breast cancer risk,
while intake of meat, mushrooms, yellow and green vegetables, coffee, and green tea, current leisure-time exercise, and
education were significantly associated with a decreased risk. Three SNPs were significantly associated with a breast
cancer risk in multivariate analysis: rs2046210 (per allele OR = 1.37 [95% CI: 1.11-1.70]), rs3757318 (OR = 1.33[1.05-1.69]),
and rs3803662 (OR = 1.28 [1.07-1.55]). In 2046210 risk allele carriers, leisure-time exercise was associated with a significantly
decreased risk for breast cancer, whereas current smoking and high BMI were associated with a significantly
decreased risk in non-risk allele carriers.
Conclusion: In Japanese women, rs2046210 and 3757318 located near the ESR1 gene are associated with a risk of breast
cancer, as in other Asian women. However, our findings suggest that exercise can decrease this risk in allele carriers.
Keywords: Japanese women, Asian, Breast cancer, Lifestyle, Leisure-time exercise, Parity, Single nucleotide
polymorphisms, rs2046210, rs3757318, ESR1Background
Data in the National Statistics of Cancer Registries by
Region (1975–2004) indicate that the prevalence of
breast cancer in Japan has increased steadily since 1975.
More than 60,000 patients had breast cancer in 2008
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reproduction in any medium, provided the ormalignant tumor in Japanese women [1]. Additionally,
the Vital Statistics Japan database of the Ministry of
Health, Labor and Welfare indicates that mortality due
to breast cancer in Japan has increased since 1960, with
more than 10,000 deaths from breast cancer in 2011 [2].
The relationship of lifestyle factors, including food and
nutrition, physical activity, body composition, environ-
mental factors, and reproductive factors, with breast
cancer risk have been widely studied, mainly in Europe
and the United States, and much evidence linking cancer
to these factors has been accumulated. According to thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Mizoo et al. BMC Cancer 2013, 13:565 Page 2 of 15
http://www.biomedcentral.com/1471-2407/13/5652007 World Cancer Research Fund/American Institute for
Cancer Research (WCRF/AICR) Second Expert Report,
the evidence that breastfeeding decreases the breast can-
cer risk and that alcohol increases this risk is described as
“convincing” [3]. In postmenopausal women, evidence
that body fat and adult attained height increase breast
cancer risk is also stated to be “convincing”. However, the
evidence of a relationship of other foods with breast can-
cer risk remains at the level of “limited-no conclusion”.
Thus, it is important to identify risk factors for breast can-
cer with the goal of prevention through efficient screening
and surveillance.
In the United States, a breast cancer risk assessment
tool based on a statistical model known as the “Gail
model” has been produced by the National Cancer Insti-
tute (NCI) [4,5]. However, this model has been developed
from epidemiological data in Caucasians and it may be in-
appropriate to apply the Gail model in the Japanese popu-
lation [6]. However, there are few epidemiological studies
of breast cancer risk in Japanese women and a breast can-
cer risk model applicable to Japanese women has yet to be
established.
Regarding genetic factors, genome-wide association
studies (GWAS) have identified several breast cancer sus-
ceptibility single nucleotide polymorphisms (SNPs) [7].
However, most of these studies were also conducted in
subjects with European ancestry, with some in popula-
tions with Chinese ancestry or in African Americans.
There is only one such study in subjects with Japanese
ancestry. However, allele frequencies related to breast
cancer risk and the extent of linkage disequilibrium dif-
fer among races. Thus, the validity of the reported asso-
ciations of SNPs with breast cancer needs to be tested
in a Japanese population.
Current findings suggest that the interactions between
breast cancer susceptibility SNPs and breast cancer risk
are not as strong as those for BRCA1 or BRCA2 gene
mutation. However, carriers of risk SNP alleles are more
common compared with carriers of BRCA1 or BRCA2
mutation. Evaluation of the need to incorporate SNPs
into a breast cancer risk model requires examination of
the influence of these SNPs and established breast cancer
risk factors to determine whether these are mutually con-
founding factors. Moreover, such findings might allow risk
allele carriers to reduce their incidence of breast cancer
through guidance on lifestyle habits.
The current study was performed to add to the relatively
small number of studies that have examined genomic fac-
tors such as SNPs in combination with non-genomic fac-
tors such as those associated with lifestyle. We first aimed
to validate whether reported breast cancer susceptibility
SNPs are applicable in the Japanese population. We then
examined the possible confounding effects on breast can-
cer risk of SNPs and lifestyle factors such as food, nutrition,physical activity, body composition, environment factors
and reproductive factors.
Methods
Subjects
A multicenter population-based case–control study was
conducted between December 2010 and November 2011 in
Japan. The subjects were consecutive patients with non-
invasive or invasive breast cancer aged over 20 years old
who were treated at Okayama University Hospital,
Okayama Rousai Hospital and Mizushima Kyodo Hospital
in Okayama and at Kagawa Prefecture Central Hospital in
Kagawa. The controls were women aged over 20 years old
without a history of breast cancer who underwent breast
cancer screening at Mizushima Kyodo Hospital and
Okayama Saiseikai Hospital in Okayama and at Kagawa
Prefectural Cancer Detection Center in Kagawa. All sub-
jects gave written informed consent before enrollment
in the study. A blood sample (5 ml) used for SNP ana-
lysis was collected from each subject. Subjects were also
given questionnaires that they completed at home and
mailed back to Okayama University Hospital. The study
was approved by the institutional ethics committee on
human research at Okayama University.
Survey of lifestyle
A survey of lifestyle was performed using an 11-page
self-administered questionnaire that included questions
on age, height and body weight (current and at 18 years
old), cigarette smoking, alcohol drinking, intake of 15
foods items, intake of 4 beverages, leisure-time exercise
(current and at 18 years old), menstruation status, age at
first menstruation, age at first birth, parity, breastfeeding,
age at menopause, hormone replacement therapy (HRT),
history of benign breast disease, familial history of breast
cancer, and education. Controls answered the survey
based on their current status and patients referred to
their prediagnostic lifestyle.
Body mass index (BMI) was calculated as body weight/
square of height. Former or current alcohol drinkers were
asked to give the frequency per week and type of drink
usually consumed (beer, wine, sake, whisky, shochu, or
others). The alcoholic content of each drink was taken to
be 8.8 g per glass (200 ml) of beer, and 20 g per glass of
sake (180 ml), wine (180 ml), shochu (110 ml) and whisky
(60 ml) [8]. Alcohol intake per day (g/day) was calculated
as follows: (total alcohol content per occasion × frequency
of consumption per week)/7. Women who currently en-
gaged in leisure-time exercise were asked to give the in-
tensity of physical activity per occurrence and frequency
per week. Metabolic equivalent (MET) values of 10, 7, 4,
and 3 METs were assigned for strenuous-, moderate-,
low-, and very low intensity activities per occurrence, re-
spectively [9], to allow calculation of the intensity of
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week). A family history of breast cancer included mother,
sisters and daughters (first-degree family history). History
of benign breast disease included the non-cancerous
breast. Clinical data on patients were obtained from hos-
pital medical records.
Selection of SNPs
Sixteen breast cancer-associated SNPs were identified from
previous GWAS [7] and candidate-gene association
studies: ATM/11q22-rs1800054 [10], 8q24-rs1562430 [11],
MAP3K1/Chr5-rs889132 [10,12], 2q-rs4666451 [10],
8q24-rs13281615 [10,12,13], TTNT3/11p15-rs909116
[11], 5q-rs30099 [10], IGF1/12q23.2-795399 [10,14],
ESR1/6q25.1-rs2046210 [15,16], CAPSP8/2q33-34-rs1045485
[10], 2q35-rs13387042 [10], ESR1/6q25.1-rs3757318
[11], TNRC9/16q12-rs3803662 [12,17], FGFR2/10q26-
rs2981282 [10,12], LSP1/11p15.5-rs381798 [12], and
HCN1/5p12- rs98178 [10]. Risk alleles associated with
breast cancer were identified with reference to the Japanese
Single Nucleotide Polymorphism (JSNP) database [18].
SNP genotyping
Genomic DNA was isolated from whole blood with a Taq-
Man® Sample-to-SNP™ kit (Applied Biosystems, Foster City,
CA, USA). Samples were analyzed by a TaqMan genotyping
assay using the StepOne™ real-time polymerase chain reac-
tion (PCR) system (Applied Biosystems) in a 96-well array
plate that included four blank wells as negative controls.
The PCR profile consisted of an initial denaturation step at
95°C for 10 min, 40 cycles of 92°C for 15 sec, and 60°C for
1 min. PCR products were analyzed by StepOne™ Software
Ver2.01 (Applied Biosystems). To assess the quality of
genotyping, we conducted re-genotyping of a randomly se-
lected 5% of samples and obtained 100% agreement.
Statistical analysis
For all analyses, significance was defined as a p-value <0.05.
Associations between lifestyle and breast cancer risk were
estimated by computing age adjusted odds ratios (OR)
and their 95% confidence intervals (CI) from logistic re-
gression analyses. Height was categorized as ≤150, 151–
155, 156–160 and >160 according to quartile. Weight was
categorized as <50, 50–54.9, 55–59.9 and ≥60 according
to quartile. BMI was categorized as ≤20, 20–21.9, 22–23
and ≥24 according to quartile. Alcohol intake per day (g/day)
was categorized as 0, <5, 5–10 and ≥10 g/day according to
quartile. Food intake, including meat, fish, egg, soy, milk,
fruits, green and yellow vegetables and mushrooms, was
categorized as ≤1, 2–4 and 5 times/week. Beverage intake
including coffee and green tea was categorized as ≤1, 2–3
and ≥3 cups/day. Intensity of physical activity in leisure
time was categorized as 0, <6, 6–11.9, 12–23.9 and ≥24
METs/week. Age at menarche was classified as ≤12, 13and ≥14 years old, parity as 0, 1–2 and ≥3, and age at first
childbirth as <25, 25–29 and ≥30 years old. Education
level was categorized as high school or less, two-year col-
lege, and university or higher.
In analysis of SNPs, accordance with the Hardy-
Weinberg equilibrium was checked in controls using a
chi-squared test. The associations between genotype and
the risk of breast cancer were estimated by computing
OR and the 95% CI from logistic regression analyses. Per
allele OR was calculated using 0, 1 or 2 copies of the risk
allele (a) as a continuous variable. The reported OR and
95% CI denote the risk difference when increasing the
number of risk alleles by one. Two models of analyses
were performed, with the first model adjusted only for
age and the second model adjusted for factors that were
significantly associated with breast cancer risk in this
study (multivariate adjustment).
For SNPs associated with breast cancer, we classified
subjects as risk allele carriers or non-risk allele carriers
and examined associations of lifestyle factors with
breast cancer risk in these subgroups. Two models were
also used in this analysis, with the second model ad-
justed for factors that were significantly associated with
breast cancer risk in the first model.
All statistical analyses were performed with Statis-
tical Analysis System software JMP version 9.0.3 (SAS
Institute).
Results
A total of 515 patients and 527 controls agreed to par-
ticipate in the study and gave written informed consent.
Of these women, 476 patients (92.4%) and 464 controls
(88.8%) returned self-administered questionnaires. In 2
cases, blood samples could not be obtained because of
brittle vessels and in another 2 cases SNP genotyping
could not be performed because of poor DNA amplifica-
tion. Thus, the final data set for analysis included 472
patients and 464 controls with completed questionnaires
and SNP genotyping.
Adjusted OR with 95% CIs for lifestyle factors are
shown in Table 1. BMI ≥24 (vs. 20–21.9) and current or
former smoker (vs. never) were associated with a signifi-
cantly increased risk for breast cancer. Meat intake ≥2
times/week (vs. ≤once/week), mushroom intake (vs. ≤once/
week), yellow and green vegetable intake (vs. ≤once/week),
coffee intake 2–3 cups/day (vs. <1 cup/day), green tea in-
take 2–3 cups/day (vs. <1 cup/day), current leisure-time ex-
ercise (vs. none), intensity of physical activity in leisure-
time exercise 6–23.9 METS/week (vs. 0 METS/week), and
university education (vs. high school or less) were all asso-
ciated with a significantly decreased risk for breast cancer.
Height, alcohol intake, age at first menstruation, parity,
age at first birth, and familial history of breast cancer have
generally been considered to be associated with breast
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this study.
In analysis of SNPs, deviation from the Hardy-Weinberg
equilibrium (P <0.05 by chi square test) was found for
rs1800054 and rs1045485, and thus these SNPs were
excluded from analysis. The minor allele frequencies
were <0.05 for rs4666451 and rs104548, and these SNPs
were also excluded, leaving 12 SNPs for analysis. Multiva-
riate ORs were adjusted for factors that were found to be
significantly associated with breast cancer: BMI, smoking
status, meat intake, mushroom intake, yellow and green
vegetable intake, coffee intake, green tea intake, leisure-
time exercise and education level.
Age adjusted ORs and multivariate ORs with 95% CIs
for independent SNPs in all subjects and in subjects strati-
fied by menopausal status are shown in Table 2. In all
women, three SNPs were significantly associated with
breast cancer risk in multivariate adjustment: rs2046210
(per allele OR = 1.37 [95% CI:1.11-1.70]), rs3757318 (per
allele OR = 1.33 [1.05-1.69] and rs3803662 (per allele =
1.28 [1.07-1.55]). rs2046210 and rs3757318, both of which
are located on 6q25.1, are not in strong linkage disequilib-
rium (LD) (D = 0.68, r2 = 0.21) according to Hap-Map JTP
[19]. Among pre-menopausal women, s3803662 (per allele
OR = 1.58 [95% CI: 1.17-2.16]) and rs2046210 (per allele
OR = 1.70 [95% CI: 1.24-2.35]) were significantly associ-
ated with breast cancer risk in multivariate adjustment.
Among post-menopausal women, there were no SNPs sig-
nificantly associated with breast cancer risk.
A subgroup analysis was performed for rs2046210 and
rs3757318. For rs2046210, leisure time exercise was asso-
ciated with a significantly decreased breast cancer risk in
risk allele carriers (AA +AG), but not in non-risk allele
carriers (GG). In contrast, BMI ≥ 24 and current smoking
were associated with a significantly increased breast can-
cer in non-risk allele carriers (GG), but not in risk allele
carriers (AA +AG). Intensity of physical activity in leisure
exercise of 12.0-23.9 METS/week and university education
were associated with breast cancer risk in risk allele and
non-risk allele carriers (Table 3). For rs3757318, BMI ≥ 24
was associated with a significantly increased breast cancer
risk in risk allele carriers (GG), but not in risk allele car-
riers (AA +AG). University education and current smo-
king were associated with breast cancer risk in risk allele
and non-risk allele carriers (Table 4).
Discussion
Associations of breast cancer risk with lifestyle factors and
SNPs alone and in combination were examined in a case–
control study in 472 patients and 464 controls. Reproduc-
tive factors such as early age at first menstruation, late age
at menopause, late age at first birth, nulliparity, and no
breastfeeding have been associated with an increase in
breast cancer risk [20], including in the Japanese population[21]. In our study, parity and breastfeeding showed a ten-
dency for an association with decreased breast cancer risk,
but this association was not significant; and age at first
menstruation, age at first birth, and age at menopause were
not significantly associated with breast cancer risk. In most
previous studies, comparisons were made using categories
for age at first menstruation of 12–13 and >15 years old
[22] and age at first birth of ≤24 and >30 years old [23]. In
the current study, the sample sizes for women who
were >15 years old at first menstruation and >30 years
old at first birth were too small to analyze correctly,
which is a limitation in the study.
The associations of food and nutrition with breast can-
cer risk have been summarized by the WCRF/AICR [3].
The effects of some foods on breast cancer are unclear,
but we found that intake of meat, mushrooms, yellow and
green vegetables, coffee and green tea was associated with
decreased breast cancer risk. The evidence that alcohol is
associated with breast cancer was judged to be “convin-
cing” by the WCRF/AICR, but we did not find this associ-
ation, which is consistent with other Japanese studies. The
frequency and amount of food consumption depends on
cultures and customs in different countries, and this may
cause the factors and threshold level for breast cancer risk
to also vary in the respective countries.
Cigarette smoking [24,25] is also considered to be asso-
ciated with increased breast cancer risk, while leisure-time
exercise [26] is associated with decreased breast cancer
risk, including in the Japanese population. The mean BMI
of the Asian population, including the Japanese popula-
tion, is lower than that in non-Asians [27]. However, we
found that BMI ≥24 is associated with increased breast
cancer risk, as found in other Japanese studies [28].
A high education level has been associated with in-
creased breast cancer risk, but this may be explained by
highly educated women having a high rate of nulliparity
and being older at first birth. However, in Japan, social
advances and college attendance have only become more
common for women in recent years, and thus education
level may not correlate well with social status and an un-
wed state. Instead, more highly educated women are
more likely to be involved in preventive health behavior
such as exercise, non-smoking, no alcohol intake and
avoidance of obesity, compared to women with less edu-
cation, and some studies have associated a higher educa-
tion level with a decreased breast cancer risk [29,30].
The current study has several limitations. First, selection
bias may have influenced the results because we enrolled
women who underwent breast cancer screening as con-
trols. In Japan, the rate of breast cancer screening was no
more than about 25% in 2010 [31]. Thus, women who
undergo screening may have more interest in trying to
maintain their health and may have a family history
of cancer, which may have eliminated the significant
Table 1 Adjusted odds ratios and 95% confidence intervals for lifestyle factors in 472 cases and 464 controls
(recruitment period: December 2010 to November 2011)
Variables Case (n = 472) Control (n = 464) ORa (95% CIs)
n (%) n (%)
Age (year) (mean ± SD) 54.72 ± 12.45 53.56 ± 11.00
Menopausal status
Pre 280 (59) 271 (58)
Post 192 (41) 193 (42)
Height (cm)
≤150 95 (20) 78 (17) 1.16 (0.78-1.71)
151-155 147 (32) 145 (32) Ref.
156-160 152 (33) 156 (34) 0.99 (0.72-1.36)
>160 72 (15) 81 (18) 0.93 (0.63-1.38)
Weight (Kg)
≤50 159 (34) 173 (37) 0.97 (0.69-1.36)
51-55 112 (24) 118 (26) Ref.
56 -60 92 (20) 78 (17) 1.24 (0.83-1.85)
>60 104 (22) 93 (20) 1.18 (0.80-1.73)
BMI (Kg/m2)
20 102 (22) 96 (21) 1.39 (0.96-2.01)
20-21.9 118 (25) 150 (33) Ref.
22-23.9 104 (22) 102 (22) 1.28 (0.89-1.84)
≥24 139 (30) 112 (24) 1.54 (1.08-2.19)
Smoking status
Never 406 (87) 432 (94) Ref.
Current or former 60 (13) 28 (6) 2.49 (1.56-4.06)
Alcohol drinking
Never 240 (51) 218 (47) ref.
Current or former 231 (49) 243 (53) 0.91 (0.70-1.18)
Alcohol intake (g/day)
0 240 (51) 218 (48) ref.
<5 140 (30) 130 (29) 1.02 (0.75-1.39)
5-10 53 (11) 62 (14) 0.82 (0.54-1.24)
10> 36 (8) 45 (10) 0.75 (0.46-1.21)
Meat intake (times/week)
≤1 101 (22) 66 (14) Ref.
2-4 297 (64) 307 (67) 0.65 (0.45-0.92)
≥5 67 (14) 88 (19) 0.51 (0.32-0.80)
Soy intake (times/week)
≤1 45 (10) 49 (11) Ref.
2-4 236 (50) 227 (50) 1.12 (0.72-1.76)
≥5 188 (40) 182 (40) 1.09 (0.69-1.72)
Fish intake (times/week)
≤1 103 (22) 94 (20) Ref.
2-4 297 (64) 314 (68) 0.85 (0.62-1.18)
≥5 67 (14) 53 (11) 1.09 (0.68-1.74)
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Table 1 Adjusted odds ratios and 95% confidence intervals for lifestyle factors in 472 cases and 464 controls
(recruitment period: December 2010 to November 2011) (Continued)
Eggs intake (times/week)
≤1 108 (23) 95 (21) Ref.
2-4 238 (51) 247 (54) 0.86 (0.62-1.20)
≥5 120 (26) 112 (25) 0.96 (0.66-1.41)
Milk intake (times/week)
≤1 84 (18) 82 (18) Ref.
2-4 157 (34) 135 (30) 1.14 (0.78-1.67)
≥5 226 (48) 238 (52) 0.92 (0.64-1.31)
Fruit intake (times/week)
≤1 112 (24) 112 (24) Ref.
2-4 172 (37) 149 (32) 1.11 (0.79-1.57)
≥5 184 (39) 199 (43) 0.86 (0.61-1.21)
Mushrooms intake (times/week)
≤1 156 (34) 120 (26) Ref.
2-4 247 (53) 261 (57) 0.73 (0.54-0.98)
≥5 61 (13) 77 (17) 0.60 (0.40-0.91)
Green and yellow vegetables intake (times/week)
≤1 47 (10) 28 (6) Ref.
2-4 231 (50) 204 (46) 0.66 (0.39-1.09)
≥5 183 (40) 212 (48) 0.48 (0.29-0.80)
Coffee intake (times/week)
<1 132 (28) 103 (22) Ref.
1 154 (33) 158 (34) 0.77 (0.55-1.09)
2-3 135 (29 160 (35) 0.68 (0.48-0.96)
≥4 45 (10) 40 (9) 0.91 (0.55-1.51)
Green tea intake (times/week)
<1 200 (43) 182 (40) Ref.
1 151 (33) 133 (29) 0.97 (0.71-1.33)
2-3 63 (14) 87 (19) 0.63 (0.43-0.93)
≥4 48 (10) 55 (12) 0.72 (0.46-1.12)
Leisure-time exercise
None 254 (54) 214 (46) Ref.
Current 214 (46) 248 (54) 0.70 (0.54-0.91)
Intensity of physical activityb (METs/week)
0 254 (56) 214 (47) Ref.
>6.0 51 (11) 42 (9) 1.05 (0.67-1.65)
6.0-11.9 44 (10) 60 (13) 0.61 (0.39-0.93)
12.0-23.9 48 (11) 80 (17) 0.51 (0.34-0.75)
≥24.0 52 (12) 61 (13) 0.70 (0.46-1.07)
Age at menarche (year)
≤12 140 (30) 201 (44) 0.88 (0.616-1.25)
13 109 (23) 113 (25) Ref.
≤14 217 (47) 144 (31) 1.25 (0.882-1.78)
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Table 1 Adjusted odds ratios and 95% confidence intervals for lifestyle factors in 472 cases and 464 controls
(recruitment period: December 2010 to November 2011) (Continued)
Parity
0 86 (20) 75 (17) Ref.
1-2 247 (57) 265 (59) 0.74 (0.511‐1.06)
≥3 102 (23) 107 (24) 0.76 (0.495‐1.15)
Age at first childbirth (year)
<25 151 (40) 142 (37) 1.22 (0.89-1.68)
25-29 162 (43) 187 (49) Ref.
≥30 63 (17) 50 (13) 1.46 (0.96-2.25)
Breastfeeding
No 125 (27) 104 (23) Ref.
Yes 339 (73) 355 (77) 0.77 (0.57-1.04)
History of benign breast disease
No 351 (79) 354 (79) Ref.
Yes 93 (21) 92 (21) 1.03 (0.74-1.42)
Family history of breast cancer
No 391 (88) 373 (88) Ref.
Yes 53 (12) 52 (12) 0.98 (0.65-1.47)
History of HRT use
No 424 (92) 412 (90) Ref.
Yes 35 (8) 45 (10) 0.76 (0.47-1.21)
Education
High school or less 259 (55) 196 (43) Ref.
Two-year college 144 (31) 144 (31) 0.78 (0.57-1.05)
University 64 (14) 120 (26) 0.41 (0.29-0.59)
aOR is adjusted for age. bIntensity of physical activity in leisure-time exercise. Significant dates are showed in boldface. OR, odds ratio; CI, confidence interval; BMI,
body mass index; HRT, hormone replacement therapy.
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cancer risk in our study. Second, recall bias may have influ-
enced the results because of the use of self-administered
questionnaires. In particular, data from patients might lack
accuracy because their answers reflected their behavior be-
fore diagnosis.
In all subjects, 3 of the 16 SNPs analyzed in the study
were significantly associated with breast cancer risk.
These included rs2046210 and rs3757318, which are lo-
cated at 6q25.1, in proximity to the estrogen receptor 1
gene (ESR1). ESR1 encodes an estrogen receptor (ERα),
a ligand-activated transcription factor composed of sev-
eral domains important for hormone binding, DNA
binding, and activation of transcription [32]. ERα is
mainly expressed in the uterus, ovary, bone, and breast
in females [33], ERα is also overexpressed in 60-70% of
cases of breast cancer and is involved in the disease
pathology. Although these SNPs are located in the same
chromosome region, they are not in strong LD based on
the HapMap Project. Potential involvement of bothSNPs in regulation of ESR1 is unclear [14,34]. rs2046210
is located 29 kb upstream of the first untranslated exon.
The risk allele frequency of rs2046210 is 33.3% in Euro-
peans (HapMap-CEU), 37.8% in Chinese (Hap Map-
HCB) and 30.0% in Japanese (HapMap-JTP) [19]. Our
result indicated a 27% risk allele frequency, which was
about the same as that in HapMap-JTP. Thus, the risk
allele frequency of Asians differs little from that of
Europeans. Several studies have associated rs2046210
with breast cancer risk [15,34-36]. Guo et al. found a
significant association between rs2046210 and breast can-
cer risk in the overall population (per allele OR 1.14,
95% CI =1.10–1.18) and in Asians (per allele OR 1.27, 95%
CI =1.23–1.31) and Europeans (per allele OR 1.09, 95%
CI =1.07–1.12), indicating that rs2046210 has a larger
effect in Asians [34]. Our results also suggest that
rs2046210 is significantly associated with breast cancer
risk in Japanese subjects.
Turnbull et al. first reported a significant association
of rs3757318 with breast cancer risk [11]. rs3757318 is
Table 2 Odds ratio with 95% confidence intervals for individual SNPs in all subjects and in subjects stratified by menopausal status
All women (n = 936) Premenopausal (n = 385) Postmenopausal (n = 551)
SNP No. of Adjusted ORb Multivariate ORc No. of Adjusted ORb Multivariate ORc o. of Adjusted ORb Multivariate ORc
Gene/location Genotypea Case/Control OR (95% CI) OR (95% CI) Case/Control OR (95% CI) OR (95% CI) Ca /Control OR (95% CI) OR (95% CI)
rs1562430 CC 7/4 Ref. Ref. 2/3 Ref. Ref. Ref. Ref.
/8q24 TC 96/102 0.54 (0.14-1.85) 0.62 (0.15‐2.32) 33/42 1.24 (0.19-9.85) 1.10 (0.15-10.05) 5/1 0.24 (0.01-1.54) 0.35 (0.02-2.80)
TT 369/351 0.61 (0.16-2.05) 0.67 (0.16‐2.45) 155/146 1.64 (0.27-12.63) 1.72 (0.24-15.14) 63/60 0.24 (0.01-1.52) 0.29 (0.01-2.25)
Per allele 1.05 (0.79-1.39) 1.02 (0.75‐1.39) 1.08 (0.81-1.45) 1.62 (1.08-2.44) 14/205 1.07 (0.85-1.36) 0.80 (0.56-1.14)
rs889132 AA 76/91 Ref. Ref. 34/36 Ref. Ref. Ref. Ref.
MAP3K1/5q CA 227/211 1.27 (0.89-1.83) 1.27 (0.86‐1.88) 91/95 0.96 (0.55-1.65) 0.82 (0.45-1.50) 42/55 1.59 (0.98-2.58) 1.57 (0.91-2.76)
CC 164/160 1.21 (0.83-1.76) 1.21 (0.81‐1.81) 64/61 1.07 (0.60-1.92) 0.98 (0.52-1.84) 36/116 1.35 (0.82-2.23) 1.30 (0.74-2.30)
Per allele 1.07 (0.89-1.29) 1.07 (0.88‐1.31) 1.08 (0.81-1.45) 1.11 (0.83-1.49) 00/99 1.07 (0.85-1.36) 1.05 (0.81-1.36)
rs13283615 AA 75/75 Ref. Ref. 29/31 Ref. Ref. ref. ref.
/8q24 GA 211/206 1.04 (0.71-1.51) 1.09 (0.73‐1.65) 73/80 0.97 (0.53-1.76) 1.13 (0.60-2.17) 46/44 1.10 (0.68-1.79) 1.17 (0.67-2.05)
GG 180/177 1.03 (0.70-1.51) 1.02 (0.67‐1.55) 86/78 1.14 (0.63-2.05) 1.18 (0.62-2.24) 38/126 0.97 (0.58-1.61) 1.09 (0.61-1.97)
Per allele 1.01 (0.84-1.21) 1.00 (0.81‐1.22) 1.11 (0.84-1.47) 1.03 (1.00-1.05) 94/99 0.95 (0.74-1.21) 0.99 (0.76-1.28)
rs981782 TT 166/149 Ref. Ref. 67/64 Ref. Ref. Ref. Ref.
HCN1/5p12 TG 220/234 0.85 (0.64-1.14) 0.82 (0.60‐1.13) 88/98 0.85 (0.54-1.33) 0.78 (0.48-1.26) 99/85 0.87 (0.59-1.27) 0.83 (0.54-1.29)
GG 82/76 0.96 (0.66-1.41) 0.88 (0.58‐1.34) 31/28 1.03 (0.56-1.91) 0.97 (0.50-1.90) 32/136 0.93 (0.57-1.52) 0.76 (0.43-1.34)
Per allele 0.95 (0.79-1.14) 0.97 (0.80‐1.17) 1.00 (0.75-1.35) 1.01 (0.74-1.38) 51/48 0.93 (0.73-1.18) 0.86 (0.66-1.13)
rs3803662 CC 74/91 Ref. Ref. 24/42 Ref. Ref. Ref. Ref.
TNRC9/16q12 TC 230/227 1.25 (0.88-1.79) 1.32 (0.89‐1.96) 89/96 1.59 (0.90-2.85) 1.50 (0.81-2.80) 50/49 1.08 (0.68-1.72) 1.25 (0.73-2.16)
TT 160/142 1.41 (0.97-2.08) 1.61 (1.06‐2.45) 72/53 2.29 (1.25-4.26) 2.29 (1.20-4.46) 41/131 1.04 (0.63-1.71) 1.27 (0.72-2.24)
Per allele 1.18 (0.98-1.42) 1.28 (1.07‐1.55) 1.54 (1.15-2.09) 1.58 (1.17-2.16) 88/89 1.00 (0.78-1.28) 1.07 (0.83-1.39)
rs381798 TT 339/347 Ref. Ref. 138/140 Ref. Ref. Ref. Ref.
LSP1/11p15.5 CT 120/107 1.14 (0.85-1.55) 1.07 (0.77‐1.49) 46/49 0.92 (0.58-1.48) 1.00 (0.60-1.68) 01/207 1.30 (0.87-1.94) 1.18 (0.75-1.86)
CC 10/5 2.04 (0.72-6.60) 1.63 (0.52‐5.66) 4/1 3.98 (0.58-78.39) 3.29 (0.42-68.89) 74/58 1.65 (0.46-6.55) 1.39 (0.32-6.31)
Per allele 1.19 (0.91-1.56) 1.11 (0.83‐1.49) 1.07 (0.70-1.64) 1.21 (0.77-1.90) 6/4 1.27 (0.90-1.81) 1.14 (0.78-1.66)
rs2046210 GG 213/244 Ref. Ref. 83/107 Ref. Ref. Ref. Ref.
ESR1/6q25.1 AG 194/185 1.21 (0.92-1.59) 1.22 (0.90‐1.64) 78/72 1.41 (0.92-2.17) 1.63 (1.03-2.61) 30/137 1.11 (0.78-1.59) 0.99 (0.67-1.48)
AA 61/34 2.03 (1.29-3.25) 2.16 (1.32‐3.59) 27/14 2.46 (1.23-5.10) 2.93 (1.40-6.40) 16/113 1.69 (0.93-3.14) 1.69 (0.84-3.50)
Per allele 1.34 (1.10-1.63) 1.37 (1.11‐1.70) 1.49 (1.10-2.03) 1.70 (1.24-2.35) 34/20 1.23 (0.95-1.59) 1.14 (0.86-1.51)
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Table 2 Odds ratio with 95% confidence intervals for individual SNPs in all subjects and in subjects stratified by menopausal status (Continued)
rs909116 CC 166/178 Ref. Ref. 71/64 Ref. Ref. Ref. Ref.
LSP/11p15.5 CT 225/228 1.08 (0.81-1.43) 1.04 (0.77‐1.42) 88/106 0.76 (0.49-1.18) 0.90 (0.55-1.47) 95/114 1.36 (0.94-1.97) 1.20 (0.79-1.83)
TT 79/57 1.49 (0.99-2.24) 1.40 (0.90‐2.19) 30/23 1.21 (0.64-2.30) 1.23 (0.62-2.48) 137/122 1.72 (1.02-2.90) 1.69 (0.94-3.09)
Per allele 1.18 (0.97-1.42) 1.15 (0.93‐1.41) 0.98 (0.72-1.32) 1.11 (0.81-1.52) 49/34 1.32 (1.03-1.69) 1.24 (0.95-1.63)
rs30099 CC 225/216 Ref. Ref. 93/84 Ref. Ref. Ref. Ref.
/5q TC 205/198 0.82 (0.52-1.29) 1.08 (0.80‐1.45) 82/84 0.87 (0.57-1.33) 0.96 (0.61-1.53) 132/132 1.08 (0.76-1.54) 1.21 (0.80-1.83)
TT 42/50 0.99 (0.76-1.30) 0.86 (0.52‐1.41) 15/25 0.53 (0.26-1.06) 0.51 (0.24-1.08) 123/114 1.12 (0.61-2.06) 1.19 (0.58-2.45)
Per allele 0.93 (0.76-1.13) 0.98 (0.79‐1.22) 0.78 (0.57-1.06) 0.85 (0.92-1.16) 27/25 1.04 (0.81-1.36) 1.12 (0.83-1.50)
rs2981282 CC 220/226 Ref. Ref. 86/94 Ref. Ref. Ref. Ref.
FGFR2 /10q26 TC 210/190 1.15 (0.87-1.50) 1.19 (0.89‐1.60) 91/81 1.23 (0.81-1.87) 1.48 (0.94-2.35) 134/132 1.10 (0.77-1.58) 1.08 (0.72-1.62)
TT 41/45 0.92 (0.58-1.47) 0.84 (0.50‐1.40) 13/17 0.89 (0.41-1.92) 1.07 (0.46-2.50) 119/109 0.95 (0.53-1.71) 0.76 (0.38-1.48)
Per allele 1.03 (0.84-1.25) 1.02 (0.82‐1.27) 1.04 (0.75-1.43) 1.27 (0.91-1.78) 28/28 1.04 (0.80-1.34) 0.94 (0.71-1.24)
rs795399 TT 255/249 Ref. Ref. 90/107 Ref. Ref. Ref. Ref.
IGF1/12q23.2 CT 180/173 0.84 (0.51-1.36) 1.05 (0.78‐1.41) 82/65 1.49 (0.97-2.30) 1.56 (0.98-2.48) 165/142 0.80 (0.56-1.15) 0.78 (0.52-1.18)
CC 34/41 1.03 (0.78-1.35) 0.85 (0.49‐1.45) 15/20 0.86 (0.41-1.77) 1.04 (0.46-2.27) 98/108 0.87 (0.44-1.70) 0.93 (0.43-1.99)
Per allele 0.96 (0.79-1.18) 0.97 (0.78‐1.21) 1.13 (0.83-1.55) 1.25 (0.91-1.72) 19/21 0.87 (0.66-1.14) 0.88 (0.66-1.17)
rs3757318 GG 249/281 Ref. Ref. 95/111 Ref. Ref. Ref. Ref.
ESR1/6q25.1 AG 182/162 1.27 (0.97-1.67) 1.25 (0.93‐1.69) 76/72 1.25 (0.82-1.91) 1.22 (0.77-1.92) 154/170 1.27 (0.88-1.81) 1.20 (0.79-1.80)
AA 34/19 2.01 (1.13-3.68) 2.05 (1.09‐3.97) 14/8 2.02 (0.83-5.25) 1.90 (0.73-5.25) 106/90 1.96 (0.92-4.37) 2.14 (0.88-5.49)
Per allele 1.34 (1.08-1.66) 1.33 (1.05‐1.69) 1.30 (0.93-1.83) 1.34 (0.95-1.91) 20/11 1.32 (1.00-1.76) 1.27 (0.93-1.75)
aAlleles on upper line are common alleles; bAdjusted for age; cMultivariate adjusted for age, BMI, smoking, meat intake, mushroom intake, green and yellow vegetable intake, coffee intake, green tea intake, leisure-time
exercise and education. Significant dates are showed in boldface. OR, odds ratio; CI, confidence interval.
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Table 3 Age-adjusted odds ratio and multivariate adjusted odds ratio with 95% confidence intervals for lifestyle factors in rs2046210
Risk allele carriers (AA + AG) n = 474 Non-risk allele carriers (GG) n = 457
Case n = 255/Control n = 219 Case n = 213/Control n = 244
n/n ORa (95% CI) p ORb (95% CI) p n/n O a (95% CI) p ORc (95% CI) p
Age (years) 54.0/53.9 55.8/53.2
Menopausal status Pre 148/133 130/137
Post 107/86 83/107
Height (cm) ≤150 40/39 1.03 (0.58-1.83) 0.93 0.96 (0.53-1.74) 0.89 55/39 1.3 (0.78-2.9) 0.29 1.19 (0.66-2.14) 0.57
151-155 76/77 Ref. Ref. 68/68 Ref Ref.
156-160 89/66 1.38 (0.88-2.16) 0.16 1.44 (0.91-2.29) 0.12 63/89 0.7 (0.48-1.3) 0.27 0.89 (0.53-1.48) 0.64
>160 46/34 1.41 (0.81-2.47) 0.23 1.62 (0.91-2.91) 0.10 25/47 0.5 (0.32-1.08) 0.09 0.51 (0.25-0.99) 0.05
BMI (Kg/m2) 20 59/46 1.27 (0.75-2.14) 0.37 1.13 (0.67-1.94) 0.64 43/50 1.6 (0.93-2.81) 0.09 1.54 (0.84-2.82) 0.16
20-21.9 69/67 Ref. Ref. 48/82 Ref Ref.
22-23.9 58/50 1.09 (0.66-1.80) 0.75 0.97 (0.58-1.63) 0.92 43/52 1.4 (0.82-2.40) 0.22 1.47 (0.83-2.63) 0.19
≥24 65/53 1.17 (0.71-1.94) 0.53 1.09 (0.65-1.82) 0.74 74/59 2.0 (1.26-3.43) <0.01 1.91 (1.11-3.29) 0.02
Smoking status Never 222/201 Ref. Ref. 180/230 Ref Ref.
Current or former 29/15 1.78 (0.93-3.51) 0.08 1.61 (0.83-3.21) 0.16 31/13 3.8 (1.94-7.98) <0.01 3.86 (1.87-8.37) <0.01
Alcohol drinking Never 129/107 Ref. Ref. 108/111 Ref Ref.
Current or former 125/109 0.97 (0.67-1.40) 0.97 1.07 (0.73-1.57) 0.74 105/133 0.9 (0.62-1.33) 0.61 0.87 (0.56-1.33) 0.51
Alcohol intake (g/day) 0 129/107 Ref. Ref. 108/111 Ref Ref.
<5 75/56 1.12 (0.72-1.74) 0.61 1.22 (0.78-1.92) 0.39 64/73 0.9 (0.64-1.54) 0.98 0.98 (0.60-1.61) 0.94
5-10 28/32 0.75 (0.42-1.34) 0.34 0.88 (0.49-1.60) 0.68 25/30 0.9 (0.51-1.72) 0.85 0.92 (0.46-1.80) 0.80
10> 20/19 0.88 (0.44-1.74) 0.71 0.94 (0.46-1.89) 0.85 16/26 0.7 (0.35-1.38) 0.31 0.55 (0.24-1.22) 0.14
Leisure-time exercise No 143/97 Ref. Ref. 110/116 Ref Ref.
Yes 110/121 0.62 (0.43-0.89) 0.01 0.60 (0.41-0.87) <0.01 101/127 0.7 (0.52-1.12) 0.17 0.74 (0.49-1.11) 0.14
Intensity of physical activityd (met/week) 0 143/99 Ref. Ref. 109/119 Ref Ref.
>6.0 25/23 0.79 (0.42-1.48) 0.45 0.72 (0.38-1.37) 0.32 25/19 1.3 (0.70-2.63) 0.37 1.20 (0.59-2.48) 0.61
6.0-11.9 20/28 0.49 (0.26-0.92) 0.03 0.46 (0.24-0.86) 0.02 22/32 0.6 (0.34-1.17) 0.15 0.66 (0.34-1.28) 0.22
12.0-23.9 27/36 0.52 (0.29-0.91) 0.02 0.53 (0.30-0.94) 0.03 21/44 0.4 (0.26-0.85) 0.01 0.45 (0.24-0.83) 0.01
≥24.0 30/32 0.65 (0.37-1.14) 0.13 0.68 (0.38-1.20) 0.18 22/29 0.7 (0.40-1.38) 0.35 0.70 (0.36-1.36) 0.30
Age at menarche ≤12 70/92 0.73 (0.45-1.19) 0.73 0.72 (0.44-1.19) 0.20 68/109 1.0 (0.63-1.81) 0.80 0.98 (0.56-1.70) 0.93
(year) 13 66/55 Ref. Ref. 43/58 Ref Ref.
≤14 116/68 1.20 (0.74-1.93) 1.20 1.15 (0.71-1.89) 0.57 99/75 1.3 (0.78-2.25) 0.29 1.62 (0.93-2.84) 0.09
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Table 3 Age-adjusted odds ratio and multivariate adjusted odds ratio with 95% confidence intervals for lifestyle factors in rs2046210 (Continued)
Parity 0 54/35 Ref. Ref. 31/40 Ref. Ref.
1-2 123/122 0.63 (0.38-1.04) 0.07 0.66 (0.40-1.10) 0.11 124/143 0.95 (0.55-1.64) 0.85 1.12 (0.61-2.09) 0.71
≥3 54/53 0.65 (0.36-1.15) 0.14 0.65 (0.36-1.17) 0.15 46/53 0.94 (0.50-1.76) 0.84 1.29 (0.64-2.62) 0.48
Age at first childbirth <25 78/68 1.21 (0.77-1.90) 0.40 1.08 (0.68-1.71) 0.74 72/74 1.22 (0.78-1.91) 0.38 1.17 (0.71-1.91) 0.54
(year) 25-29 87/89 Ref. Ref. 75/97 Ref. Ref.
≥30 33/22 1.55 (0.84-2.90) 0.16 1.45 (0.77-2.76) 0.25 30/28 1.39 (0.77-2.54) 0.27 1.77 (0.92-3.45) 0.09
Breastfeeding No 72/51 Ref. Ref. 51/53 Ref. Ref.
Yes 178/165 0.76 (0.50-1.16) 0.21 0.77 (0.50-1.17) 0.22 159/189 0.83 (0.53-1.30) 0.42 1.02 (0.62-1.69) 0.93
Family history of No 209/180 Ref. Ref. 178/192 Ref. Ref.
Breast cancer Yes 31/24 1.11 (0.63-1.97) 0.55 1.12 (0.63-2.00) 0.71 22/28 0.82 (0.45-1.50) 0.75 1.07 (0.57-2.05) 0.83
Education High school or less 135/99 Ref. Ref. 123/96 Ref. Ref.
Two-year college 81/63 0.93 (0.61-1.42) 0.74 0.95 (0.62-1.47) 0.83 60/81 0.62 (0.40-0.95) 0.03 0.59 (0.37-0.94) 0.03
University 36/55 0.48 (0.29-0.79) <0.01 0.48 (0.29-0.79) <0.01 28/65 0.35 (0.21-0.59) <0.01 0.38 (0.22-0.66) <0.01
aOR is adjusted for age.
bMultivariate adjusted for leisure-time exercise and education.
cMultivariate adjusted for BMI, smoking state, intensity of physical activity and education.
dIntensity of physical activity and education. Significant dates are showed in boldface.
OR, odds ratio; CI, confidence interval; BMI, body mass index.
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Table 4 Age-adjusted odds ratio and multivariate adjusted odds ratio with 95% confidence intervals for lifestyle factors in rs3757318
Risk allele carriers(AA + AG) n = 397 non-risk allele carriers(GG) n = 530
Case n = 216/Control n = 181 Case n = 249/Control n = 281
n/n ORa (95%CI) p ORb (95% CI) p n/n a (95% CI) p ORc (95% CI) p
Age (years) 54.23/53.30 55.28/53.76
Menopausal status Pre 124/101 154/170
Post 92/80 95/111
Height (cm) ≤150 36/28 1.24 (0.66-2.34) 0.50 1.46 (0.68-3.16) 0.33 58/50 1 (0.65-1.77) 0.78 1.01 (0.60-1.69) 0.98
151-155 62/63 Ref. Ref. 84/80 R ref.
156-160 78/51 1.57 (0.96-260) 0.07 1.57 (0.86-2.90) 0.14 72/105 0 (0.44-1.05) 0.08 0.73 (0.47-1.15) 0.18
>160 36/38 1.00 (0.55-1.80) 0.99 0.58 (0.26-1.24) 0.16 34/43 0 (0.46-1.39) 0.43 0.89 (0.50-1.59) 0.70
BMI(Kg/m2) <20 48/37 1.36 (0.77-2.40) 0.26 1.11 (0.54-2.29) 0.77 54/59 1 (0.95-2.59) 0.06 1.60 (0.95-2.69) 0.08
20-21.9 59/60 Ref. Ref. 54/90 R Ref.
22-23.9 47/35 1.35 (0.77-2.40) 0.24 1.57 (0.80-3.12) 0.19 57/66 1 (0.86-2.30) 0.40 1.29 (0.78-2.14) 0.32
≥24 57/48 1.18 (0.69-2.01) 0.51 1.14 (0.60-2.17) 0.68 81/63 2 (1.29-3.37) <0.01 1.89 (1.16-3.10) 0.01
Smoking status Never 186/168 Ref. Ref. 214/262 R Ref.
Current or former 25/11 2.15 (1.05-4.71) 0.04 2.73 (1.07-7.65) 0.04 34/17 2 (1.53-5.40) <0.01 2.39 (1.27-4.65) <0.01
Alcohol drinking Never 114/90 Ref. Ref. 124/127 R Ref.
Current or former 101/89 0.93 (0.62-1.39) 0.71 0.99 (0.60-1.65) 0.97 125/153 0 (0.63-1.28) 0.55 0.95 (0.65-1.38) 0.78
Alcohol intake 0 114/90 Ref. Ref. 124/127 R Ref.
(g/day) <5 59/45 1.08 (0.67-1.76) 0.75 1.12 (0.61-2.04) 0.72 78/84 1 (0.67-1.51) 0.98 1.11 (0.72-1.70) 0.64
5-10 27/27 0.81 (0.44-1.49) 0.50 0.88 (0.41-1.90) 0.75 25/35 0 (0.44-1.41) 0.43 0.89 (0.49-1.63) 0.71
10> 13/16 0.65 (0.29-1.41) 0.27 0.78 (0.27-2.14) 0.63 22/29 0 (0.44-1.52) 0.54 0.66 (0.33-1.28) 0.22
Leisure-time No 122/80 Ref. Ref. 127/133 R Ref.
Exercise Yes 93/101 0.58 (0.39-0.87) <0.01 0.78 (0.47-1.27) 0.32 119/146 0 (0.58-1.17) 0.27 0.84 (0.59-1.21) 0.35
Intensity of physical activityd(met/week) 0 122/81 Ref. Ref. 126/137 R Ref.
>6.0 23/17 0.87 (0.44-1.76) 0.70 1.62 (0.68-4.03) 0.28 28/25 1 (0.68-2.27) 0.48 1.19 (0.64-2.25) 0.58
6.0-11.9 21/25 0.55 (0.28-1.04) 0.07 0.58 (0.27-1.21) 0.15 23/34 0 (0.37-1.22) 0.20 0.69 (0.37-1.28) 0.24
12.0-23.9 19/32 0.39 (0.20-0.73) <0.01 0.73 (0.33-1.56) 0.41 29/48 0 (0.37-1.06) 0.08 0.62 (0.36-1.06) 0.08
≥24.0 23/26 0.56 (0.29-1.06) 0.07 0.67 (0.31-1.42) 0.29 27/35 0 (0.45-1.39) 0.42 0.84 (0.47-1.50) 0.55
Age at menarche ≤12 63/73 1.00 (0.59-1.70) 0.99 1.67 (0.85-3.33) 0.14 73/127 0 (0.47-1.24) 0.28 0.74 (0.45-1.22) 0.24
(year) 13 52/51 Ref. Ref. 57/61 R Ref.
≤14 99/56 1.39 (0.82-2.35) 0.22 1.74 (0.90-3.37) 0.10 115/88 1 (0.70-1.81) 0.63 1.02 (0.62-1.68) 0.92
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Table 4 Age-adjusted odds ratio and multivariate adjusted odds ratio with 95% confidence intervals for lifestyle factors in rs3757318 (Continued)
Parity 0 49/24 Ref. Ref. 37/50 Ref. Ref.
1-2 110/105 0.48 (0.27-0.84) <0.01 0.55 (0.19-1.54) 0.25 132/160 0.98 (0.60-1.62) 0.95 1.19 (0.70-2.05) 0.52
≥3 36/48 0.34 (0.17-0.65) <0.01 0.35 (0.12-1.04) 0.06 65/58 1.36 (0.77-2.40) 0.29 1.74 (0.95-3.21) 0.07
Age at first childbirth <25 60/60 1.05 (0.64-1.71) 0.86 0.97 (0.56-1.66) 0.90 88/82 1.35 (0.89-2.05) 0.15 1.19 (0.77-1.84) 0.43
(year) 25-29 72/77 88/110 Ref. Ref.
≥30 34/19 1.96 (1.03-3.80) 0.04 1.82 (0.88-3.85) 0.11 29/31 1.17 (0.66-2.10) 0.59 1.27 (0.69-2.33) 0.45
Breastfeeding No 65/38 Ref. Ref. 59/65 Ref. Ref.
Yes 150/143 0.60 (0.38-0.95) 0.03 0.93 (0.36-2.43) 0.89 183/211 0.91 (0.61-1.38) 0.67 1.07 (0.69-1.65) 0.77
Family history of No 173/143 Ref. Ref. 212/229 Ref. Ref.
Breast cancer Yes 24/19 1.04 (0.55-2.00) 0.79 1.30 (0.56-3.07) 0.54 28/33 0.91 (0.53-1.57) 0.93 0.90 (0.51-1.58) 0.72
Education High school or less 113/80 Ref. Ref. 144/115 Ref. Ref.
Two-year college 74/54 0.99 (0.62-1.57) 0.96 1.02 (0.58-1.79) 0.94 66/90 0.60 (0.40-0.91) 0.01 0.63 (0.42-0.96) 0.03
University 27/45 0.43 (0.24-0.76) <0.01 0.33 (0.16-0.67) 0.00 36/74 0.40 (0.25-0.64) <0.01 0.45 (0.28-0.73) <0.01
aOR is adjusted for age.
bMultivariate adjusted for smoking state, leisure-time exercise, party, age of first children, breastfeeding and education. cMultivariate adjusted for BMI, smoking state, and education. dIntensity of physical activity and
education. Significant dates are showed in boldface. OR, odds ratio; CI, confidence interval; BMI, body mass index.
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http://www.biomedcentral.com/1471-2407/13/565located 200 kb upstream of ESR1. The risk allele fre-
quency of rs3757318 is 6.6% in Europeans (HapMap-
CEU), 33% in Chinese (HapMap-HCB) and 25% in
Japanese (HapMap-JTP) [19]. We found a 22% risk allele
frequency, consistent with HapMap-JTP. Thus, the risk
allele frequency for rs3757318 varies between Europeans
and Asians. In an analysis of the association between
rs2046210 and rs12662670 as a surrogate for rs3757318
and breast cancer risk, Heins et al. found that that per
allele OR for rs3757318 was higher in Asians (1.29, 95%
CI 1.19–1.41) than in Europeans (1.12, 95% CI 1.08–
1.17) [31]. These results suggest that screening for the
rs3757318 genotype may be important in Asian women.
We also found that SNPs associated with breast cancer
differed with regard to menses state, with rs2046210 and
rs3803662 associated with breast cancer risk in premeno-
pausal women. rs3803662 lies 8 kb upstream of TNRC9
and was found to have a significant association with breast
cancer risk by Easton et al. [12]. TNRC9 is located on
chromosome 16q12 and consists of seven exons. The pro-
tein encoded by this gene is a member of the high mobility
group box (HMG-box) family. TNRC9 is expressed in brain
and breast tissue, and has a higher expression level in
breast cancer compared to that in normal tissue [37]. The
risk allele frequency of rs3803662 is 24% in Europeans
(HapMap-CEU), 72% in Chinese (HapMap-HCB) and 60%
in Japanese (HapMap-JTP) [19]. Thus, Asian populations
have a higher risk allele frequency than Europeans. How-
ever, Chen et al. found that rs3803662 was significantly
associated with breast cancer in Europeans [17], but that
this relationship was unclear in Asians [38]. Among the
breast cancer-associated SNPs found in the current
study, rs2046210 and rs3757318 are located near ESR1
and are related to breast cancer risk in Asians. To exa-
mine whether lifestyle factors associated with breast can-
cer risk vary in risk allele and non-risk allele carriers, we
performed a subgroup analysis. Leisure-time exercise
were associated with a decreased breast cancer risk in
rs2046210 risk allele carriers. Although low-penetrance
susceptibility SNPs may confer only a small effect on
breast cancer risk alone, the risk for development of
breast cancer in a risk allele carrier is about 1.2-1.3 fold
higher than that in non-carriers. However, our results
suggest that risk allele carriers can reduce their breast
cancer risk through exercise, whereas obesity and smo-
king may increase breast cancer risk in non risk-allele
carriers. An understanding of the mechanisms underlying
the different lifestyle factors associated with breast cancer
in rs2046210 and rs3757318 risk allele and non-risk al-
lele carriers may clarify the effects of these SNPs located
near ESR1. Examination of interactions between SNPs
and lifestyle factors in a larger Japanese population is
needed to confirm the current findings for SNPs, lifestyle
factors and breast cancer.Conclusions
This case–control study showed that rs2046210 and
rs3757318 located near the ESR1 gene and rs3808662
located on TNRC9 are associated with breast cancer risk
in Japanese women. Our results suggest that leisure-time
exercise can reduce the breast cancer risk in rs2046210
risk allele carriers, whereas smoking and obesity may in-
crease the breast cancer risk in non-risk allele carriers.
Further studies are required to confirm the validity of the
association of these SNPs and lifestyle factors with breast
cancer risk in the Japanese population.
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